A Pilot Phase II, Randomised, Double-Blind, Placebo-Controlled, Multi-Centred Safety, Tolerability and Preliminary Efficacy Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter (AF/AFL) Recurrence in Subjects Post-Conversion Form AF
Latest Information Update: 14 Mar 2022
At a glance
- Drugs Vernakalant (Primary)
- Indications Atrial fibrillation; Atrial flutter
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Correvio Pharma
- 25 Sep 2006 Status change
- 02 Aug 2006 Status change
- 05 Dec 2005 New trial record.